STOCK TITAN

Armistice Capital/Steven Boyd disclose 935,724 shares (4.99%) in Medicus Pharma

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Schedule 13G amendment filed by Armistice Capital, LLC and Steven Boyd discloses a shared beneficial ownership of 935,724 common shares of Medicus Pharma Ltd., representing 4.99% of the class. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder, and that Mr. Boyd, as managing member, may be deemed to beneficially own the shares. Voting and dispositive power are reported as shared (935,724 shares) with no sole voting or dispositive power.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Reporting persons hold a sub-5% stake, a routine disclosure with limited market impact.

The Schedule 13G/A shows a 4.99% position held indirectly via a master fund with voting and disposition powers exercised by Armistice Capital. Because the position is under the 5% threshold, the filing is consistent with passive investor reporting and does not signal an intent to influence control. The disclosure improves ownership transparency but is unlikely to materially affect valuation or trigger regulatory thresholds.

TL;DR: Governance implications are limited; shared voting power is disclosed but no control assertion is made.

The filing clarifies that the Master Fund is the direct holder while Armistice Capital and Steven Boyd exercise shared voting and dispositive power pursuant to an investment management agreement. The Master Fund expressly disclaims beneficial ownership by virtue of limited voting/disposition authority. This structure and the joint filing statement are standard for investment managers and do not indicate coordinated group control or a change in corporate governance.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in Medicus Pharma Ltd. (MDCX)?

The filing reports a shared beneficial ownership of 935,724 shares, equal to 4.99% of the class.

Who holds voting and dispositive power over the reported shares?

The filing states shared voting and shared dispositive power of 935,724 shares, with no sole voting or dispositive power.

Through which vehicle does Armistice Capital hold the Medicus Pharma shares?

The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager.

Does the Schedule 13G/A indicate an intent to change control of Medicus Pharma?

No. The signers certify the securities were acquired and are held in the ordinary course of business and not to influence control.

Who signed the Schedule 13G/A on behalf of Armistice Capital?

The document is signed by Steven Boyd as Managing Member of Armistice Capital, dated August 14, 2025.
Medicus Pharma Ltd

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data

35.78M
14.73M
35.91%
14.9%
1.87%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
Canada
W. CONSHOHOCKEN